Last reviewed · How we verify

Enstilar® foam — Competitive Intelligence Brief

Enstilar® foam (Enstilar® foam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical corticosteroid + vitamin D analog combination. Area: Dermatology.

marketed Topical corticosteroid + vitamin D analog combination Glucocorticoid receptor; vitamin D receptor (VDR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Enstilar® foam (Enstilar® foam) — Icahn School of Medicine at Mount Sinai. Enstilar foam combines a potent corticosteroid (betamethasone dipropionate) with a vitamin D analog (calcipotriene) to reduce inflammation and normalize skin cell differentiation in psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Enstilar® foam TARGET Enstilar® foam Icahn School of Medicine at Mount Sinai marketed Topical corticosteroid + vitamin D analog combination Glucocorticoid receptor; vitamin D receptor (VDR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical corticosteroid + vitamin D analog combination class)

  1. Icahn School of Medicine at Mount Sinai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Enstilar® foam — Competitive Intelligence Brief. https://druglandscape.com/ci/enstilar-foam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: